Pharma Jan Samadhan scheme

Date: March 13, 2015

National Pharmaceutical Pricing Authority (NPPA) Pharma Jan Samadhan scheme drug regulation

Pharma Jan Samadhan scheme: A scheme for redressal of consumers’ grievances

Union Chemicals and Fertilizers Minister Ananth Kumar in New Delhi has launched Pharma Jan Samadhan scheme, for redressal of grievances of consumers related to drug pricing and availability of medicines. The scheme is a web-enabled system created by National Pharmaceutical Pricing Authority (NPPA).The scheme will provide consumers with an online facility to redress their complaints related to over-pricing of medicines, non-availability of medicines, sale of new medicines without prior price approval of NPPA and refusal of supply for sale of any medicine without  sufficient reason. NPPA will initiate action on any complaint within 48 hrs of its receipt.

prepare ias

National Pharmaceutical Pricing Authority (NPPA)

NPPA is an organization of the Government of India was established under the Drugs (Prices Control) Order, 1995  to regulate the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.The organization is also entrusted with the task of recovery of amounts overcharged by manufacturers for controlled drugs from the consumers & also monitors the prices of decontrolled drugs.

Functions of National Pharmaceutical Pricing Authority (NPPA)

 1- Implementation and enforcement of the provisions of the Drugs (Prices Control) Order and also Deal with all legal matters arising out of the decisions of the Authority

 2- Provide assistance to the Central Government in the parliamentary matters relating to the drug pricing.

 3-Monitoring the availability of drugs, identify shortages, if any, and to take remedial steps

 4-Maintaining data on production, exports and imports, market share of individual companies, profitability of companies etc, for bulk drugs and formulations

 5- Rendering advice to the Central Government on changes/ revisions in the drug policy